As healthcare professionals, our understanding of Parkinson's disease (PD) is crucial in providing effective patient care. PD is a progressive, neurodegenerative disorder that affects movement, muscle control, and balance.
PD primarily affects the dopamine-producing neurons in the substantia nigra, a region of the brain that controls movement. The exact cause is unknown, but both genetic and environmental factors are implicated. The characteristic motor symptoms are due to the loss of dopamine, resulting in an imbalance of excitatory and inhibitory signals in the basal ganglia.
PD typically presents with resting tremor, bradykinesia, rigidity, and postural instability. However, non-motor symptoms such as depression, cognitive impairment, and autonomic dysfunction often precede the motor symptoms and significantly affect the quality of life.
PD is primarily diagnosed clinically, based on the presence of cardinal motor symptoms and their response to dopaminergic therapy. Neuroimaging and genetic testing can support the diagnosis but are not routinely used due to their limited sensitivity and specificity.
While there is no cure for PD, the goal of treatment is to manage symptoms and improve quality of life. Pharmacological therapy, primarily with levodopa and dopamine agonists, is the mainstay of treatment. Non-pharmacological interventions, including physical therapy and lifestyle modifications, also play a crucial role.
Understanding Parkinson's disease is paramount for healthcare professionals. By recognizing the clinical features, understanding the pathophysiology, and being aware of the latest treatment strategies, we can ensure that our patients receive the best possible care. Continuous research and advancements in this field offer hope for better management strategies and, ultimately, a cure for this debilitating disease.
1.
What is a "cancer vaccine" and is it the same as a COVID vaccine?
2.
Advances in "next generation" photoactive cancer therapy
3.
Nonmelanoma skin cancer has been linked to occupational exposure to solar UVR.
4.
Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis
5.
FDA Approves New Bladder Cancer First-Line Standard of Care.
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
The latest research on Iron Binding Capacity: The Little-Known Factor That Could Impact Your Health v
3.
The latest Hematocrit: An Overview of Red Blood Cell Health
4.
Contemporary Trends in Oncology and Patient Outcomes
5.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
3.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation